Boehringer Ingelheim Vetmedica, Inc.
3902 Gene Field Road
St. Joseph, Missouri 64506
Value Through Innovation19 June 2013
November 22, 2011
Boehringer Ingelheim Announces Equine Research Award Recipients
Boehringer Ingelheim Announces Equine Research Award Recipients
Studies to bolster equine disease research efforts
Inc., (BIVI) announces the recipients of the first annual Equine Research Awards. This year, BIVI awarded a total of $75,000 ($25,000 to each recipient) to fund three separate studies regarding Equine Rhinitis Virus (ERV) for completion in 2012.
The BIVI Equine Research Awards are open to veterinarians, diagnosticians, and public and private researchers in the United States and Canada. The awards are designed to help advance the diagnosis, treatment and understanding of equine diseases and will focus on one specific disease area each year. For 2011, the equine disease of focus was Equine Rhinitis Virus (ERV). The winning research proposals address a wide variety of issues surrounding ERV diagnosis, symptomatology and treatment.
Following are the 2011 research award recipients and their research proposals, which were recognized at the American Association of Equine Practitioners (AAEP) Conference in San Antonio, Texas:
- Melissa Mazan, DVM, Tufts University – Is Equine Rhinitis Virus Associated with Exacerbation of Inflammatory Airway Disease?
- Nicola Pusterla, DVM, the University of California – Davis – Prevalence of Nasal Shedding of Equine Rhinitis Virus in Healthy Horses and Horses with Respiratory Signs
- Andres Diaz-Mendez, DVM, the University of Guelph – Response of Equine Airway Epithelium to Equine Rhinitis A Virus Infection and Surveillance
The proposals were reviewed and selected by an independent review board consisting of noted equine veterinary academicians and practitioners throughout the U.S.
"We felt it was essential to ensure impartiality when selecting the winning proposals,‖ says, Dr. Bob Stenbom, associate director, equine professional services for BIVI. ―Our research board was comprised of a mix of academicians and practitioners and made their evaluations and selections in a truly independent fashion."
The members of the 2011 independent review board included:
- Tom Divers, DVM, DACVIM, DACVECC, Professor of Medicine Chief, Section of Large Animal Medicine College of Veterinary Medicine, Cornell University, Ithaca, N.Y.
- Rob Franklin, DVM, DACVIM, Weatherford Equine Medical Center, Weatherford, Texas
- N. Edward Robinson, B. Vet. Med., Ph.D, Matilda, R. Wilson Professor of Large Animal Clinical Sciences, Director, Equine Pulmonary Laboratory, Michigan State University, East Lansing, Mich.
- Nathan Slovis, DVM, DAVCIM, CHT, Hagyard Equine Medical Institute, Lexington, Ky.
- Julie Wilson, DVM, DACIVM, Turner Wilson Equine Consulting, Stillwater, MN
"BIVI was very pleased with the proposals the board selected and their additional input on disease areas we should focus on in the future," adds Stenbom. "We look forward to continuing the program in the years to come."
For more information regarding the Equine Research Awards please visit www.equinediseaseresearch.com.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For Boehringer Ingelheim—and its employees—carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
